Dravet syndrome: Insights into seizure and speech progression from registry data

1:1
Analysis of registry data offers critical insights into the progression of seizures and speech development in patients with Dravet syndrome.

This study utilises patient registry data to track the natural history of Dravet syndrome, focusing on how seizure frequency and speech abilities evolve over time. The findings provide a baseline for evaluating the efficacy of future therapeutic interventions.

Acces this publication
Epilepsy & Behaviour

Year of publication

2025

Source

Epilepsy & Behavior

Author

elporte M, Verbeeck J, Brambilla I, Zimmermann G, Molenberghs G, Nabbout R, et al.

You might also be interested in

ERDERA Accelerator webinar (1)

ERDERA launches Ethics & Regulatory webinar series with introductory webinar on ethics across the research continuum

ERDERA’s ethics and regulatory experts are launching a dedicated webinar series to help the rare disease research community navigate two fast-moving areas of biomedical research: Advanced Therapy Medicinal Products (ATMPs) and Artificial Intelligence.
webinar series ERDERA

Introductory webinar: Situating ethics in the research continuum

July 24 @ 3:00 pm - 4:00 pm
This webinar will present a theoretical framework for situating ethics across research activities. The framework will then be brought to life through a relevant case study discussion, giving participants a concrete reference point for the episodes ahead.
NMG workshop 2026

ERDERA National Mirror Groups workshop: Creating, evolving and utilising national registries to advance rare disease research

Held in Riga on 9–10 June, the workshop brought National Mirror Group experts, researchers, clinicians and policymakers together to exchange practical lessons on how national rare disease registries can better support research and alignment across countries.
2

ERDERA launches Clinical Trial Call 2026 to advance early‑phase clinical trials for rare diseases

ERDERA (the European Rare Diseases Research Alliance) has opened its Clinical Trial Call to support multinational early-phase clinical trials in rare diseases. The call will fund studies designed to generate robust clinical evidence, strengthen regulatory readiness and make rare disease trials more feasible across countries.

ERDERA's

search form